Cryoport joins Lonza vein-to-vein delivery network

Partnership in cell and gene therapy to provide global and fully integrated delivery solutions from manufacturing to logistics

Lonza and Cryoport have announced their partnership in the cell and gene therapy field. As a part of this commitment, Cryoport becomes Lonza's preferred partner in the transport and delivery of patient tissues on a global basis, with the continued goal of seamless service for Lonza’s customers and their patients.

"The Lonza-Cryoport collaboration is an enabling part of a wider goal for Lonza to create a network of strategic partnerships and capabilities that enable seamless vein-to-vein delivery of cell and gene therapies for its customers and their patients," said Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech. "There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency."

Both companies will work to remove the supply chain hurdles faced by developers of personalised therapeutics, including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines, as they prepare for the commercial launch of their respective therapies.

This partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services

Lonza’s network of cell and gene therapy facilities spans the US, Europe and Asia and serves both clinical and commercial customers globally.

Global network

Cryoport currently supports over 413 clinical trials and three commercial therapies in the regenerative medicine space and operates in over 100 countries around the world.

Integrating Cryoport’s logistics and bioservices solutions with Lonza’s manufacturing services and expertise will ensure a trusted and seamless supply chain and drive efficiencies in delivering innovative medicines to patients.

Our partnership agreement with Lonza will improve effectiveness, efficiency and safety throughout the cell and gene therapy manufacturing process

The goal of the partnership is to provide fully integrated solutions including, but not limited to, co-location of manufacturing, bioservices and distribution facilities to improve and enhance responsiveness and optimized product workflow, automated data management providing integrated data entry and process optimisation that reduces risk, increases transparency and improves certainty.

Jerrell Shelton, CEO, Cryoport, commented: “Our partnership agreement with Lonza will improve effectiveness, efficiency and safety throughout the cell and gene therapy manufacturing process by integrating our temperature-controlled supply chain solutions with Lonza’s manufacturing services.”

Cryoport’s logistics system aims to provide Lonza’s clients with reliable and comprehensive delivery solutions through its advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting teams of professionals.

Beyond Cryoport’s proprietary Cryoport Express® Shippers, this partnership incorporates Cryoport’s Cryoportal Logistics Management Platform and SmartPak II Condition Monitoring System, which brings to the market an integrated IT solution that provides risk mitigation and Cryoport’s unique Chain of Compliance for regulatory solutions.

Companies